Código QR (código de barras bidimensional)

Erdafitinib Antagonizes ABCB1-Mediated Multidrug Resistance in Cancer Cells

ABCB1 overexpression is known to contribute to multidrug resistance (MDR) in cancers. Therefore, it is critical to find effective drugs to target ABCB1 and overcome MDR. Erdafitinib is a tyrosine kinase inhibitor (TKI) of fibroblast growth factor receptor (FGFR) that is approved by the FDA to treat...

ver descrição completa

Na minha lista:
Principais autores: Weiguo Feng, Meng Zhang, Zhuo-Xun Wu, Jing-Quan Wang, Xing-Duo Dong, Yuqi Yang, Qiu-Xu Teng, Xuan-Yu Chen, Qingbin Cui, Dong-Hua Yang
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2020-06-01
coleção:Frontiers in Oncology
Assuntos:
erdafitinib
ABCB1
multidrug resistance
reversal effect
cancer
Acesso em linha:https://www.frontiersin.org/article/10.3389/fonc.2020.00955/full
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados